Table 3 Patient’s details
No | Gender | Age | ECOG | Previous lines of liver metastases therapy | HIFU treatment | Tumor responsea | Systematic treatment after HIFU | Recurrence after first HIFU | Outcome (month) |
|---|---|---|---|---|---|---|---|---|---|
1 | Male | 71 | 0 | – | HIFU | PR | Tegafur | Hepatic | Expired (24) |
2 | Female | 67 | 1 | – | HIFU | CR | Tegafur | Extrahepatic | Alive with recurrence (44) |
3 | Male | 62 | 0 | – | TACE + HIFU | CR | – | Hepatic | Alive with recurrence (44) |
4 | Female | 55 | 1 | RFA | HIFU | CR | Paclitaxel + Tegafur | Extrahepatic | Alive with recurrence (41) |
5 | Male | 62 | 1 | RFA; TACE | HIFU | CR | Tegafur | – | Alive without recurrence (29) |
6 | Male | 71 | 0 | SOX | HIFU | CR | SOX | – | Alive without recurrence (26) |
7 | Male | 64 | 1 | – | TACE + HIFU | SD | Nab-paclitaxel + Tegafur | Extrahepatic | Expired (11) |
8 | Male | 59 | 0 | SOX | HIFU | PR | – | Hepatic | Alive with recurrence (6) |